Gemeinsamer Bundesausschuss

Resolution

of the Federal Joint Committee on the discontinuation of the benefit assessment procedure according to Section 35a SGB V Deutivacaftor/ tezacaftor/ vanzacaftor (cystic fibrosis, at least one non-Class I mutation, ≥ 6 years)

of 22 January 2026

The Federal Joint Committee (G-BA) decided the following at their session on 22 January 2026:

Following the finding that the proprietary medicinal product Alyftrek with the combination of active ingredients deutivacaftor/ tezacaftor/ vanzacaftor exceeded the turnover limit of EUR 30 million according to Section 35a, paragraph 1, sentence 12 SGB V, the ongoing benefit assessment procedure according to Section 35a, paragraph 1, sentence 11 SGB V in conjunction with Chapter 5 Section 12, No. 1 Rules of Procedure of the G-BA on the combination of active ingredients deutivacaftor/ tezacaftor/ vanzacaftor in the approved therapeutic indication "for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one non-Class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene" is discontinued.

The justification to this resolution will be published on the website of the G-BA at www.g-ba.de.

Berlin, 22 January 2026

Federal Joint Committee (G-BA)
in accordance with Section 91 SGB V
The Chair

Prof. Hecken